Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 01, 2020 16:05 ET | Source: Aduro Biotech, Inc.

Aduro Biotech Stockholders Approve Merger Agreement with Chinook Therapeutics

One-for-Five Reverse Stock Split to be Effective October 2, 2020 BERKELEY, Calif., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADURO), a clinical-stage biopharmaceutical company...
August 03, 2020 16:05 ET | Source: Aduro Biotech, Inc.

Aduro Biotech Provides Business Update and Reports Second Quarter 2020 Financial Results

BERKELEY, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the A Proliferation...
June 24, 2020 08:15 ET | Source: Aduro Biotech, Inc.

Aduro Biotech Announces First Patient Dosed in Phase 1 Study of BION-1301 in IgA Nephropathy

BERKELEY, Calif., June 24, 2020 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of...
June 02, 2020 07:35 ET | Source: Aduro Biotech, Inc.

Aduro Biotech Presents Nonclinical and Phase 1 Healthy Volunteer Data for BION-1301 at the 57th ERA-EDTA Virtual Congress

BION-1301 was well-tolerated, with no serious adverse events (SAEs), treatment discontinuations or events meeting stopping criteria, across a wide range of dosesPharmacokinetics (PK) of BION-1301 were...
June 02, 2020 07:30 ET | Source: Aduro Biotech, Inc.; Chinook Therapeutics

Aduro Biotech and Chinook Therapeutics Announce Definitive Merger Agreement

– Combined Company Will Operate as Chinook Therapeutics and Advance Pipeline of Clinical-Stage Programs in Kidney Diseases, Led by Atrasentan and BION-1301 in IgA Nephropathy – Combined Company Will...
May 19, 2020 08:15 ET | Source: Aduro Biotech, Inc.

Aduro Biotech to Host Conference Call and Webcast Featuring BION-1301 Data Presented at the 57th ERA-EDTA Virtual Congress

BERKELEY, Calif., May 19, 2020 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of...
May 04, 2020 16:15 ET | Source: Aduro Biotech, Inc.

Aduro Biotech Provides Business Update and Reports First Quarter 2020 Financial Results

BERKELEY, Calif., May 04, 2020 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of...
March 09, 2020 16:15 ET | Source: Aduro Biotech, Inc.

Aduro Biotech Provides Business Update and Reports Fourth Quarter and Full Year 2019 Financial Results

BERKELEY, Calif., March 09, 2020 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of...
February 24, 2020 16:15 ET | Source: Aduro Biotech, Inc.

Aduro Biotech to Present at the Cowen and Company 40th Annual Health Care Conference

BERKELEY, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, is scheduled...
February 19, 2020 08:15 ET | Source: Aduro Biotech, Inc.

Aduro Biotech to Present at the 9th Annual SVB Leerink Global Healthcare Conference

BERKELEY, Calif., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, is scheduled...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right